Literature DB >> 6280097

Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas.

D P Braun, R D Penn, A M Flannery, J E Harris.   

Abstract

Levels of indomethacin-sensitive, glass-adherent, preculture-sensitive, and lymphocyte-mediated immunoregulatory activity were measured in peripheral blood mononuclear cells from 12 patients with intracranial astrocytomas. The levels of regulatory cell function were determined in assays of T cell immunocompetence as judged by phytohemagglutinin (PHA)-induced in vitro lymphocyte DNA synthesis. Of 6 patients studied before surgical exploration and diagnosis, 6 exhibited significantly depressed levels of PHA responsiveness in association with significantly increased levels of regulatory cell function by glass-adherent, preculture-sensitive and/or indomethacin-sensitive cells. Six patients were studied after diagnosis and treatment. Of those, 2 in remission had normal levels of immune function in association with normal levels of regulatory cell activity, whereas 2 of 4 patients who had recurrent disease had significantly depressed T cell function in association with increased glass-adherent, preculture-sensitive and/or indomethacin-sensitive regulatory cell activity. Although some alterations in lymphocyte-medicated suppressor cell activity were seen in 2 patients, those changes could not be correlated with impaired T cell function as measured in the PHA stimulation assay. The changes in regulatory cell function could not be correlated with levels of immune complexes in patient sera. These data suggest that increased levels of regulatory cell function by glass-adherent, preculture-sensitive and/or indomethacin-sensitive cells alone or in conjunction with lymphocyte and T cell depletion are a primary determinant of impaired immunocompetence in glioma patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6280097

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  13 in total

Review 1.  Microenvironmental clues for glioma immunotherapy.

Authors:  Michael Platten; Katharina Ochs; Dieter Lemke; Christiane Opitz; Wolfgang Wick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

2.  Particular features of cell-mediated immunity in patients with anaplastic gliomas. A comparison with kidney and bladder cancer patients.

Authors:  F Servadei; R Parente; M Bucci; E Beltrandi; F Tognetti; G Gaist
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

3.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

4.  Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells.

Authors:  G W Wood; R A Morantz
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

Review 5.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130

Review 6.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

7.  Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors.

Authors:  B P Barna; L R Rogers; M J Thomassen; G H Barnett; M L Estes
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Immunological studies in patients with central nervous system tumors.

Authors:  L Palma; V Moschese; E Galli; C Barbieri; V R Lombardi; P Rossi
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

9.  Blood lymphocyte subsets in patients with primary intracranial tumours. Correlation to histological tumour type and anatomical site.

Authors:  H Ullén; U Blom; H Blomgren; H von Holst
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

10.  Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer.

Authors:  K J McCormick; W R Panje
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.